Nayaka Raghavendra Babu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nayaka Raghavendra Babu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Y. Padmavathi
3 shared publications- Gudhanti Siva Naga Koteswara Rao
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai, India
2 shared publications N. Malothu
Department of Pharmaceutical Chemistry, KL College of Pharmacy, Koneru Lakshmaiah Educational Foundation, Vaddeswaram, India
2 shared publications- Rajasekhar Reddy Alavala
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai-400056, India
2 shared publications - Alisha M. Jain1 shared publication
Amani Shareef
1 shared publication
Latest Publications
- Open Access
- 13 April 2026
- Published by Pharma Research Library in Asian Journal of Medical and Pharmaceutical Sciences
- Vol. 14 (02) , 57-62
From Biodiversity to Drug Discovery: Pharmacological Significance and Conservation of Endangered Medicinal Plants
Background: Medicinal plants have served as a cornerstone for drug discovery and traditional healthcare systems for centuries. However, a significant proportion of these biologically valuable species are currently threatened due to anthropogenic pressures and ecological changes. Objective: This review aims to critically evaluate pharmacologically important endangered medicinal plants, focusing on their phytochemical composition, therapeutic potential, and conservation challenges. Methods: A comprehensive literature survey was conducted using databases such as PubMed, Scopus, and Web of Science, covering publications from 2021 to 2026. Studies were selected based on relevance to endangered status, pharmacological validation, and phytochemical characterization. Results: Several endangered plants, including Rauvolfia serpentina, Coscinium fenestratum, Angelica glauca, Chlorophytum borivilianum, and Saussurea costus, exhibit significant pharmacological activities such as antihypertensive, antimicrobial, anti-inflammatory, immunomodulatory, and anticancer effects. These activities are attributed to diverse phytoconstituents including alkaloids, flavonoids, terpenoids, and glycosides. Conclusion: Endangered medicinal plants represent a valuable yet diminishing resource for drug discovery. Integrating pharmacological research with conservation strategies is essential to ensure sustainable utilization and preservation of these species.
- 13 April 2026
- Published by Pharma Research Library in Asian Journal of Medical and Pharmaceutical Sciences
- Vol. 14 (02) , 57-62
Open AccessFrom Biodiversity to Drug Discovery: Pharmacological Significance and Conservation of Endangered Medicinal Plants
Background: Medicinal plants have served as a cornerstone for drug discovery and traditional healthcare systems for centuries. However, a significant proportion of these biologically valuable species are currently threatened due to anthropogenic pressures and ecological changes. Objective: This review aims to critically evaluate pharmacologically important endangered medicinal plants, focusing on their phytochemical composition, therapeutic potential, and conservation challenges. Methods: A comprehensive literature survey was conducted using databases such as PubMed, Scopus, and Web of Science, covering publications from 2021 to 2026. Studies were selected based on relevance to endangered status, pharmacological validation, and phytochemical characterization. Results: Several endangered plants, including Rauvolfia serpentina, Coscinium fenestratum, Angelica glauca, Chlorophytum borivilianum, and Saussurea costus, exhibit significant pharmacological activities such as antihypertensive, antimicrobial, anti-inflammatory, immunomodulatory, and anticancer effects. These activities are attributed to diverse phytoconstituents including alkaloids, flavonoids, terpenoids, and glycosides. Conclusion: Endangered medicinal plants represent a valuable yet diminishing resource for drug discovery. Integrating pharmacological research with conservation strategies is essential to ensure sustainable utilization and preservation of these species.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Spectroscopy and Chromatography
- Vol. 11, 1-16
Validated RP-HPLC Method for Simultaneous Estimation of Tadalafil and Macitentan in Bulk and Dosage Forms
Introduction: Reverse-phase high-performance liquid chromatography is a simple, quick, accurate, sensitive, and reproducible technique for quantitatively analyzing Tadalafil and Macitentan in pharmaceutical dosage form. This method is novel as it allows for the simultaneous quantification of both Tadalafil and Macitentan in a single run, which is not widely reported in existing literature. Methods: Waters Alliance-e2695 was used to perform the chromatographic separation of Tadalafil and Macitentan using an Agilent Eclipse XDB C18 (150 x 4.6 mm, 3.5 μ) column and a mobile phase that contained acetonitrile: 0.1% TFA in a 50:50% v/v ratio. At room temperature, the flow rate was found to be 1.0 ml/min, and a photodiode array detector was used to monitor the absorption at 301 nm. Results: For Tadalafil and Macitentan, the theoretical plate count was not less than 2000, and the tailing factor should not exceed 2. All measurements have a percentage relative standard deviation of peak areas that is consistently smaller than 2. Discussion: The suggested approach was validated in compliance with ICH Q2 (R1) regulations. This method was deemed simple, cost-effective, accurate, precise, and reliable for quantitative analysis of the stability study of Tadalafil and Macitentan. The novelty of this work mainly depends on the use of specific mobile phase composition, pH, column type, or detection wavelength that achieves excellent separation and peak resolution within a shorter run time. Conclusion: This study shows excellent sensitivity with low LOD/LOQ values, and superior efficiency through rapid analysis, good resolution, and robustness, making it suitable for routine quality control and pharmaceutical analysis.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Spectroscopy and Chromatography
- Vol. 11, 1-16
Validated RP-HPLC Method for Simultaneous Estimation of Tadalafil and Macitentan in Bulk and Dosage Forms
Introduction: Reverse-phase high-performance liquid chromatography is a simple, quick, accurate, sensitive, and reproducible technique for quantitatively analyzing Tadalafil and Macitentan in pharmaceutical dosage form. This method is novel as it allows for the simultaneous quantification of both Tadalafil and Macitentan in a single run, which is not widely reported in existing literature. Methods: Waters Alliance-e2695 was used to perform the chromatographic separation of Tadalafil and Macitentan using an Agilent Eclipse XDB C18 (150 x 4.6 mm, 3.5 μ) column and a mobile phase that contained acetonitrile: 0.1% TFA in a 50:50% v/v ratio. At room temperature, the flow rate was found to be 1.0 ml/min, and a photodiode array detector was used to monitor the absorption at 301 nm. Results: For Tadalafil and Macitentan, the theoretical plate count was not less than 2000, and the tailing factor should not exceed 2. All measurements have a percentage relative standard deviation of peak areas that is consistently smaller than 2. Discussion: The suggested approach was validated in compliance with ICH Q2 (R1) regulations. This method was deemed simple, cost-effective, accurate, precise, and reliable for quantitative analysis of the stability study of Tadalafil and Macitentan. The novelty of this work mainly depends on the use of specific mobile phase composition, pH, column type, or detection wavelength that achieves excellent separation and peak resolution within a shorter run time. Conclusion: This study shows excellent sensitivity with low LOD/LOQ values, and superior efficiency through rapid analysis, good resolution, and robustness, making it suitable for routine quality control and pharmaceutical analysis.
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 16 (6)
Quantitative Analysis of Irbesartan in Pharmaceutical Formulation Using MBTH Reagent
A novel, simple, sensitive and efficient method has been established for the quantification of Irbesartan in bulk and pharmaceutical formulations utilizing the MBTH reagent. The objective of this analytical validation approach is to substantiate its efficacy by laboratory trials, demonstrating that the method satisfies the requisite minimal requirements for laboratory application. 3-methyl-2-benzothiazoline hydrazone interacts with the secondary amine group of Irbesartan in the presence of the oxidizing agent cerric ammonium sulphate. The resultant blue chromogen, when analysed spectrophotometrically in the visible spectrum (400 nm-800 nm), exhibits a peak absorbance at 656 nm. This approach can be effectively utilized for quantifying drug content in pharmaceutical formulations. The analysis results have been statistically confirmed. A coefficient of determination (r²) of 0.999 indicated adherence to Beer-Lambert's law across the concentration range of 2 to10 μg/mL. The limit of quantification and limit of detection limits were determined to be 1.2 μg/mL and 0.39 μg/mL, respectively. Keywords Irbesartan; Spectrophotometrically; MBTH reagent; Validation
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 16 (6)
Quantitative Analysis of Irbesartan in Pharmaceutical Formulation Using MBTH Reagent
A novel, simple, sensitive and efficient method has been established for the quantification of Irbesartan in bulk and pharmaceutical formulations utilizing the MBTH reagent. The objective of this analytical validation approach is to substantiate its efficacy by laboratory trials, demonstrating that the method satisfies the requisite minimal requirements for laboratory application. 3-methyl-2-benzothiazoline hydrazone interacts with the secondary amine group of Irbesartan in the presence of the oxidizing agent cerric ammonium sulphate. The resultant blue chromogen, when analysed spectrophotometrically in the visible spectrum (400 nm-800 nm), exhibits a peak absorbance at 656 nm. This approach can be effectively utilized for quantifying drug content in pharmaceutical formulations. The analysis results have been statistically confirmed. A coefficient of determination (r²) of 0.999 indicated adherence to Beer-Lambert's law across the concentration range of 2 to10 μg/mL. The limit of quantification and limit of detection limits were determined to be 1.2 μg/mL and 0.39 μg/mL, respectively. Keywords Irbesartan; Spectrophotometrically; MBTH reagent; Validation
- 1 October 2023
- Published by Pleiades Publishing Ltd in Russian Journal of General Chemistry
- Vol. 93 (10) , 2684-2693
Synthesis, Antitubercular Evaluation, Molecular Docking Study, and Teratogenicity Studies of Novel Triazolo Quinazoline Hybrids
A novel series of triazole-quinazoline hybrid molecules was synthesized and characterized by spectral analyses. The H37 RV strain was used to test the newly synthesised compounds for antitubercular efficacy against Mycobacterium tuberculosis. Some of the synthesized compounds were effective compared with standard pyrazinamide at a concentration of 3.12 μg/mL. Additionally, molecular docking investigations were conducted on all synthesized compounds against the M. tuberculosis InhA protein, which is attenuated by the PT70 X-ray crystal structure, PDB ID: 2X22. Two compounds were revealed the best against 2X22, with Autodock scores of –9.13 and –8.59, respectively. To further investigate the teratogenicity of the synthesized compounds, zebrafish larvae were employed. At a concentration of 100 μM, some compounds showed no signs of abnormality.
- 1 October 2023
- Published by Pleiades Publishing Ltd in Russian Journal of General Chemistry
- Vol. 93 (10) , 2684-2693
Synthesis, Antitubercular Evaluation, Molecular Docking Study, and Teratogenicity Studies of Novel Triazolo Quinazoline Hybrids
A novel series of triazole-quinazoline hybrid molecules was synthesized and characterized by spectral analyses. The H37 RV strain was used to test the newly synthesised compounds for antitubercular efficacy against Mycobacterium tuberculosis. Some of the synthesized compounds were effective compared with standard pyrazinamide at a concentration of 3.12 μg/mL. Additionally, molecular docking investigations were conducted on all synthesized compounds against the M. tuberculosis InhA protein, which is attenuated by the PT70 X-ray crystal structure, PDB ID: 2X22. Two compounds were revealed the best against 2X22, with Autodock scores of –9.13 and –8.59, respectively. To further investigate the teratogenicity of the synthesized compounds, zebrafish larvae were employed. At a concentration of 100 μM, some compounds showed no signs of abnormality.
- 26 June 2023
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 16 (6) , 2719-2723
Development and Validation of RP-HPLC Method for the Quantitative Estimation of Rivaroxaban in Bulk and Pharmaceutical Dosage Form
Rivaroxaban (RIV) is an oral anticoagulant, used in the treatment of thromboembolic ailments, myocardial infarction, stroke, angina pectoris and various blood clotting related disorders. A sensitive RP-HPLC method was developed for the quantitative estimation of RIV in bulk and pharmaceutical dosage form using Paracetamol as internal standard (IS). The separation of drug was achieved by C18 column using Acetonitrile and water as mobile phase at a ratio of 60:40%v/v with a flow rate and wavelength of 1ml/min and 254nm respectively. The retention time of RIV and IS were found to be 4.230 and 2.980 mins. The developed method was validated according to ICH (Q2)R1 guidelines over the concentration range of 100-500ng/ml. The LOD and LOQ were found to be 8.3325ng/ml and 25.25ng/ml. The method was found to be linear (R2=0.9992), specific, accurate, precised and robust.
- 26 June 2023
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 16 (6) , 2719-2723
Development and Validation of RP-HPLC Method for the Quantitative Estimation of Rivaroxaban in Bulk and Pharmaceutical Dosage Form
Rivaroxaban (RIV) is an oral anticoagulant, used in the treatment of thromboembolic ailments, myocardial infarction, stroke, angina pectoris and various blood clotting related disorders. A sensitive RP-HPLC method was developed for the quantitative estimation of RIV in bulk and pharmaceutical dosage form using Paracetamol as internal standard (IS). The separation of drug was achieved by C18 column using Acetonitrile and water as mobile phase at a ratio of 60:40%v/v with a flow rate and wavelength of 1ml/min and 254nm respectively. The retention time of RIV and IS were found to be 4.230 and 2.980 mins. The developed method was validated according to ICH (Q2)R1 guidelines over the concentration range of 100-500ng/ml. The LOD and LOQ were found to be 8.3325ng/ml and 25.25ng/ml. The method was found to be linear (R2=0.9992), specific, accurate, precised and robust.
- 22 December 2022
- Published by Pleiades Publishing Ltd in Russian Journal of Bioorganic Chemistry
- Vol. 49 (1) , 127-138
Design, Synthesis, Anti-Tubercular Evaluation and Teratogenicity Studies of Furanyl Pyrazolo[3,4-b] Quinoline-5-Ones
We have synthesized novel pyrazolo-quinoline analogues (P1–10) in an effort to create newer antitubercular drugs against the rising bacterial resistance. NMR, IR and ESI-MS spectra were utilized to characterize the synthesised compounds. The antitubercular activity of the target compounds was evaluated against Mycobacterium tuberculosis. Six derivatives (P1–6) displayed very significant activity at 1.6 µg/mL concentration and were found to be more active than pyrazinamide standard. Thus, as per the drug susceptibility results the MIC value could be considered between 1.6 and 0.8 µg/mL. In addition, all the synthesised compounds were subjected to molecular docking studies against specific protein, Enoyl acyl carrier protein reductase (InhA) in complex with N-(4-methylbenzoyl)-4-benzylpiperidine, PDB ID: 2NSD. Among all the compounds the most effective compounds were found an Autodock score of 11.6 and 11.2 against 2NSD, respectively. Further, Zebrafish larvae have been used to test the teratogenicity of the synthesised compounds. There were no indications of abnormalities with (P2), (P4), (P5), (P6), and (P10) at 0.5 µM.
- 22 December 2022
- Published by Pleiades Publishing Ltd in Russian Journal of Bioorganic Chemistry
- Vol. 49 (1) , 127-138
Design, Synthesis, Anti-Tubercular Evaluation and Teratogenicity Studies of Furanyl Pyrazolo[3,4-b] Quinoline-5-Ones
We have synthesized novel pyrazolo-quinoline analogues (P1–10) in an effort to create newer antitubercular drugs against the rising bacterial resistance. NMR, IR and ESI-MS spectra were utilized to characterize the synthesised compounds. The antitubercular activity of the target compounds was evaluated against Mycobacterium tuberculosis. Six derivatives (P1–6) displayed very significant activity at 1.6 µg/mL concentration and were found to be more active than pyrazinamide standard. Thus, as per the drug susceptibility results the MIC value could be considered between 1.6 and 0.8 µg/mL. In addition, all the synthesised compounds were subjected to molecular docking studies against specific protein, Enoyl acyl carrier protein reductase (InhA) in complex with N-(4-methylbenzoyl)-4-benzylpiperidine, PDB ID: 2NSD. Among all the compounds the most effective compounds were found an Autodock score of 11.6 and 11.2 against 2NSD, respectively. Further, Zebrafish larvae have been used to test the teratogenicity of the synthesised compounds. There were no indications of abnormalities with (P2), (P4), (P5), (P6), and (P10) at 0.5 µM.
- 2 June 2022
- Published by Bentham Science Publishers Ltd. in Anti-Infective Agents
Synthesis, Characterization and Antitubercular Evaluation of Tetrahydrotetrazolo Quinazoline Derivatives
Background: Tuberculosis is a highly contagious disease that is one of the major causes of mortality worldwide and the leading infectious organism-related cause of death. Various tetrazole and quinazoline compounds have been successfully developed in the past for tuberculosis treatment. In this case, we planned to design the hybrid moieties by combining both tetrazole and quinazoline nucleus to create novel compounds with increased activity. Methods: 6, 6-dimethyl-5, 6, 7, 9–tetrahydrotetrazolo [5, 1-b] Quinazolin-8(4H) -one derivatives were synthesized, characterized by using spectral data. The antitubercular activity of the synthesised compounds was tested against the H37RV strain of Mycobacterium tuberculosis. In order to identify the interactions with the target protein Mtb Pks13 Thioesterase domain in complex with inhibitor, docking analysis of the final compounds was performed (Protein data bank ID: 5V41). To verify their drug-like potential, the synthesised compounds were subjected to Pharmacokinetic prediction experiments. Zebrafish larvae had been used to test the teratogenicity of the synthesised compounds. Results: At 6.25 µg/mL, compounds F4 and F7 exhibited good efficacy against Mycobacterium tuberculosis strains. Docking studies aided in determining the most likely binding mode within the binding cavity of the concerned target protein. Conclusion: Compounds containing p-fluorophenyl and p-nitrophenyl groups as substituents were found to have excellent anti-tubercular activity.
- 2 June 2022
- Published by Bentham Science Publishers Ltd. in Anti-Infective Agents
Synthesis, Characterization and Antitubercular Evaluation of Tetrahydrotetrazolo Quinazoline Derivatives
Background: Tuberculosis is a highly contagious disease that is one of the major causes of mortality worldwide and the leading infectious organism-related cause of death. Various tetrazole and quinazoline compounds have been successfully developed in the past for tuberculosis treatment. In this case, we planned to design the hybrid moieties by combining both tetrazole and quinazoline nucleus to create novel compounds with increased activity. Methods: 6, 6-dimethyl-5, 6, 7, 9–tetrahydrotetrazolo [5, 1-b] Quinazolin-8(4H) -one derivatives were synthesized, characterized by using spectral data. The antitubercular activity of the synthesised compounds was tested against the H37RV strain of Mycobacterium tuberculosis. In order to identify the interactions with the target protein Mtb Pks13 Thioesterase domain in complex with inhibitor, docking analysis of the final compounds was performed (Protein data bank ID: 5V41). To verify their drug-like potential, the synthesised compounds were subjected to Pharmacokinetic prediction experiments. Zebrafish larvae had been used to test the teratogenicity of the synthesised compounds. Results: At 6.25 µg/mL, compounds F4 and F7 exhibited good efficacy against Mycobacterium tuberculosis strains. Docking studies aided in determining the most likely binding mode within the binding cavity of the concerned target protein. Conclusion: Compounds containing p-fluorophenyl and p-nitrophenyl groups as substituents were found to have excellent anti-tubercular activity.
- 30 May 2022
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 15 (5) , 2261-2267
Development and Validation of Chemometric Assisted Fourier Transform Infrared Spectroscopic Method for Simultaneous Determination of Montelukast Sodium and Fexofenadine Hydrochloride in Pharmaceutical Dosage Forms
A new analytical method has been developed for the simultaneous estimation of Montelukast sodium and Fexofenadine hydrochloride in pharmaceutical dosage forms using chemometrically assisted Fourier Transform Infrared (FTIR) Spectroscopy. This method involves preparation of solid pellets of Montelukast sodium and Fexofenadine hydrochloride using Potassium bromide (KBr) with the aid of geometric mixing. The spectra were measured by direct measurement technique using reduced path length in absorbance mode and the equipment was configured to collect spectra at 8cm-1 resolution. The spectra were collected between the ranges of 4000cm-1 to 450cm-1. Infrared spectra of the two drugs showed different functional group peaks with base line correction; from which intense, clear and proportionate peaks at 1704cm-1 and 3421cm-1 corresponding to C=O stretching and O- H group were selected for Montelukast and Fexofenadine respectively for quantitative estimation using chemometrics. Beer-Lambert’s law was obeyed over the concentration range of 5-25 μg/mg for Montelukast and Fexofenadine. The developed method was validated according to International Conference on Harmonisation (ICH) guidelines. The validation parameters - precision, accuracy, limit of quantitation, limit of detection were determined and found to be within the limits. This method was successfully applied for analysis of marketed formulations of Montelukast sodium and Fexofenadine hydrochloride.
- 30 May 2022
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 15 (5) , 2261-2267
Development and Validation of Chemometric Assisted Fourier Transform Infrared Spectroscopic Method for Simultaneous Determination of Montelukast Sodium and Fexofenadine Hydrochloride in Pharmaceutical Dosage Forms
A new analytical method has been developed for the simultaneous estimation of Montelukast sodium and Fexofenadine hydrochloride in pharmaceutical dosage forms using chemometrically assisted Fourier Transform Infrared (FTIR) Spectroscopy. This method involves preparation of solid pellets of Montelukast sodium and Fexofenadine hydrochloride using Potassium bromide (KBr) with the aid of geometric mixing. The spectra were measured by direct measurement technique using reduced path length in absorbance mode and the equipment was configured to collect spectra at 8cm-1 resolution. The spectra were collected between the ranges of 4000cm-1 to 450cm-1. Infrared spectra of the two drugs showed different functional group peaks with base line correction; from which intense, clear and proportionate peaks at 1704cm-1 and 3421cm-1 corresponding to C=O stretching and O- H group were selected for Montelukast and Fexofenadine respectively for quantitative estimation using chemometrics. Beer-Lambert’s law was obeyed over the concentration range of 5-25 μg/mg for Montelukast and Fexofenadine. The developed method was validated according to International Conference on Harmonisation (ICH) guidelines. The validation parameters - precision, accuracy, limit of quantitation, limit of detection were determined and found to be within the limits. This method was successfully applied for analysis of marketed formulations of Montelukast sodium and Fexofenadine hydrochloride.
- Open Access
- 26 July 2021
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 33 (8) , 1923-1928
Design, Synthesis, Molecular Docking Studies and Antitubercular Evaluation of Hexahydroquinolin-2-yl Benzamide Derivatives
A new series of hexahydroquinolin-2-yl benzamide derivatives (BZ1-10) were designed and synthesized. The synthesized compounds were characterized by 1H NMR, IR and ESI-MS spectra and also subjected for molecular docking studies with the target DNA gyrase enzyme (PBD ID: 4B6C). The molecular docking results of synthesized derivatives indicated the best docking score of -5.105 and -5.02 for BZ9 and BZ4, respectively. All the synthesized compounds were screened for antitubercular activity against H37RV strain, among all, two compounds exhibited significant activity at 12.5 μg/mL and 25 μg/mL concentrations. Thus, the MIC values are in between range of 12.5 and 6.25 μg/mL concentrations. The teratogenicity assay of synthesized compounds was performed in zebrafish larvae, out of the ten compounds, BZ4, BZ6 and BZ8 compounds were found to safer at 0.5 μM concentration without any abnormalities.
- 26 July 2021
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 33 (8) , 1923-1928
Open AccessDesign, Synthesis, Molecular Docking Studies and Antitubercular Evaluation of Hexahydroquinolin-2-yl Benzamide Derivatives
A new series of hexahydroquinolin-2-yl benzamide derivatives (BZ1-10) were designed and synthesized. The synthesized compounds were characterized by 1H NMR, IR and ESI-MS spectra and also subjected for molecular docking studies with the target DNA gyrase enzyme (PBD ID: 4B6C). The molecular docking results of synthesized derivatives indicated the best docking score of -5.105 and -5.02 for BZ9 and BZ4, respectively. All the synthesized compounds were screened for antitubercular activity against H37RV strain, among all, two compounds exhibited significant activity at 12.5 μg/mL and 25 μg/mL concentrations. Thus, the MIC values are in between range of 12.5 and 6.25 μg/mL concentrations. The teratogenicity assay of synthesized compounds was performed in zebrafish larvae, out of the ten compounds, BZ4, BZ6 and BZ8 compounds were found to safer at 0.5 μM concentration without any abnormalities.
- 1 January 2020
- Published by Brieflands in Journal of Reports in Pharmaceutical Sciences
- Vol. 9 (1) , 1-10
Quantitative bioanalytical and analytical methods for estimation of ivabradine hydrochloride in pure and pharmaceutical dosage form
Introduction: New analytical and bioanalytical methods were developed for the estimation of Ivabradine hydrochloride in bulk and pharmaceutical dosage form by UV spectrophotometry and high-performance liquid chromatography (HPLC) technique. Objective: The primary objective of the study is to develop a new RP-HPLC method for estimation of Ivabradine Hydrochloride in pure and formulation and to develop a bioanalytical method for analysis of Ivabradine Hydrochloride in biological samples. The methods were validated as per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and USFDA guidelines respectively. Methods: In Reversed-phase (RP)-HPLC method developed telmisartan is the internal standard used. After liquid–liquid extraction, the analyte and the internal standard were chromatographed on Waters 125A (10 µ, 300 × 3.9 mm) C18 column using 20-µL injection volume with a run time of 15 min. An isocratic mobile phase consisting of acetonitrile and ammonium acetate buffer pH 7.8 (60:40% vol/vol) is used to separate drug and internal standard. In Spectrophotometric bioanalytical method developed for the estimation of ivabradine hydrochloride in pure and pharmaceutical dosage form. The solvent system used is absolute methanol and detected at the wavelength of 287 nm. The solvent system used is absolute methanol and detected at the wavelength of 287 nm. Results: The Analytical method is validated according to ICH guidelines over the range of 2–16 μg/ mL, showing accuracy, precision, selectivity, and robustness. For Bioanalytical method the linearity is established in the range of 500–3500 ng/mL with the regression coefficient of r2 = 0.9994. The validated spectrophotometric method is used successfully to study ivabradine hydrochloride in rat plasma and also quantitative determination in marketed tablets. Conclusion: The proposed methods were successfully applied for the quantitation of ivabradine hydrochloride in pharmaceutical dosage form with good recovery and reproducibility.
- 1 January 2020
- Published by Brieflands in Journal of Reports in Pharmaceutical Sciences
- Vol. 9 (1) , 1-10
Quantitative bioanalytical and analytical methods for estimation of ivabradine hydrochloride in pure and pharmaceutical dosage form
Introduction: New analytical and bioanalytical methods were developed for the estimation of Ivabradine hydrochloride in bulk and pharmaceutical dosage form by UV spectrophotometry and high-performance liquid chromatography (HPLC) technique. Objective: The primary objective of the study is to develop a new RP-HPLC method for estimation of Ivabradine Hydrochloride in pure and formulation and to develop a bioanalytical method for analysis of Ivabradine Hydrochloride in biological samples. The methods were validated as per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and USFDA guidelines respectively. Methods: In Reversed-phase (RP)-HPLC method developed telmisartan is the internal standard used. After liquid–liquid extraction, the analyte and the internal standard were chromatographed on Waters 125A (10 µ, 300 × 3.9 mm) C18 column using 20-µL injection volume with a run time of 15 min. An isocratic mobile phase consisting of acetonitrile and ammonium acetate buffer pH 7.8 (60:40% vol/vol) is used to separate drug and internal standard. In Spectrophotometric bioanalytical method developed for the estimation of ivabradine hydrochloride in pure and pharmaceutical dosage form. The solvent system used is absolute methanol and detected at the wavelength of 287 nm. The solvent system used is absolute methanol and detected at the wavelength of 287 nm. Results: The Analytical method is validated according to ICH guidelines over the range of 2–16 μg/ mL, showing accuracy, precision, selectivity, and robustness. For Bioanalytical method the linearity is established in the range of 500–3500 ng/mL with the regression coefficient of r2 = 0.9994. The validated spectrophotometric method is used successfully to study ivabradine hydrochloride in rat plasma and also quantitative determination in marketed tablets. Conclusion: The proposed methods were successfully applied for the quantitation of ivabradine hydrochloride in pharmaceutical dosage form with good recovery and reproducibility.